autologous nectin-4/FAP-targeted CAR-T cells
Term · Oncology and biomedicine · MLC-T-ONC-011714
A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) nectin-4 and cell surface protein fibroblast activation protein (FAP), and additionally an inducible expression cassette encoding transgenic interleukin (IL) 7 (IL-7) or 12 (IL-12), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the autologous nectin-4/FAP-targeted CAR-T cells target and bind to nectin-4-expressing tumor cells and FAP-expressing cancer associated fibroblasts (CAFs). This results in a cytotoxic T-lymphocyte (CTL) response against nectin-4-expressing tumor cells and FAP-expressing CAFs, leading to cell lysis of these cells. Upon the binding to nectin-4 and FAP and the activation of the CAR-T cells, cytokine IL-7 or IL-12 is also released. This further augments the immune responses against the tumor cells, which may include the attack of nectin-4-negative tumor cells by tumor necrosis factor alpha (TNFa). Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer. FAP, a cell surface glycoprotein, is overexpressed on CAFs but minimally expressed on normal, healthy cells.
| Identifier | MLC-T-ONC-011714 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | autologous anti-nectin4/FAP CAR-T cells; autologous anti-nectin-4/anti-FAP CAR-T cells |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011714",
"term": "autologous nectin-4/FAP-targeted CAR-T cells",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) nectin-4 and cell surface protein fibroblast activation protein (FAP), and additionally an inducible expression cassette encoding transgenic interleukin (IL) 7 (IL-7) or 12 (IL-12), with potential immunostimulating and antineoplastic activities. Upon intratumoral administration, the autologous nectin-4/FAP-targeted CAR-T cells target and bind to nectin-4-expressing tumor cells and FAP-expressing cancer associated fibroblasts (CAFs). This results in a cytotoxic T-lymphocyte (CTL) response against nectin-4-expressing tumor cells and FAP-expressing CAFs, leading to cell lysis of these cells. Upon the binding to nectin-4 and FAP and the activation of the CAR-T cells, cytokine IL-7 or IL-12 is also released. This further augments the immune responses against the tumor cells, which may include the attack of nectin-4-negative tumor cells by tumor necrosis factor alpha (TNFa). Nectin-4, a TAA belonging to the nectin family, is overexpressed in a variety of cancers, including breast, bladder, lung and pancreatic cancer. FAP, a cell surface glycoprotein, is overexpressed on CAFs but minimally expressed on normal, healthy cells.",
"synonyms": [
"autologous anti-nectin4/FAP CAR-T cells",
"autologous anti-nectin-4/anti-FAP CAR-T cells"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-nectin-4-fap-targeted-car-t-cells/"
}
Record 3,050 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.